RenaMed Biologics Inc.

Spurred on by the need to reduce mortality in end-stage renal disease, start-ups accept the challenge of trying to develop devices that improve outcomes without adding costs in an environment of low r

Pharmaceutical and medical device companies are increasingly turning to corporate venture capital as a self-funding, maybe even profitable, way to manage rapid change and gather business intelligence.